CSIMarket
 
Aligos Therapeutics Inc   (ALGS)
Other Ticker:  
 
 
Price: $0.7870 $-0.05 -5.749%
Day's High: $0.8454 Week Perf: -25.75 %
Day's Low: $ 0.79 30 Day Perf: -9.51 %
Volume (M): 125 52 Wk High: $ 1.38
Volume (M$): $ 98 52 Wk Avg: $0.86
Open: $0.81 52 Wk Low: $0.54



 Market Capitalization (Millions $) 34
 Shares Outstanding (Millions) 44
 Employees -
 Revenues (TTM) (Millions $) 16
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 90
 Capital Exp. (TTM) (Millions $) 0

Aligos Therapeutics Inc
Aligos Therapeutics Inc is a pharmaceutical company focused on developing innovative treatments for viral infections and liver diseases. The company is dedicated to addressing the unmet medical needs in these areas by utilizing cutting-edge science and research. Aligos Therapeutics aims to provide effective and safe therapies to patients around the world by leveraging its expertise in virology and liver biology. The company's mission is to improve the lives of those affected by viral infections and liver diseases through groundbreaking drug development and clinical research.


   Company Address: One Corporate Drive South San Francisco 94080 CA
   Company Phone Number: 466-6059   Stock Exchange / Ticker: NASDAQ ALGS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Promising Results from Phase 2a HERALD Study of ALG-055009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients

Published Wed, Apr 3 2024 12:01 PM UTC

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease characterized by the presence of fat, inflammation, and liver cell damage in individuals with metabolic dysfunction, such as obesity, type 2 diabetes, and dyslipidemia. Aiming to address the unmet medical needs of MASH patients, Aligos Therapeutics, a clinical stage biopharmaceutical compa...

Clinical Study

Advancements in Liver and Viral Disease Therapeutics: Aligos Therapeutics Presents Positive Clinical Data at APASL 2024

Published Wed, Mar 27 2024 12:00 PM UTC

Aligos Therapeutics, a leading biopharmaceutical company, recently presented groundbreaking clinical data at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, held in Kyoto, Japan. With a primary focus on developing novel therapeutics targeting liver and viral diseases, Aligos' presentations shed light on the promising progress...

Clinical Study

Aligos Therapeutics Ventures into Phase 2a HERALD Study for Potential MASH Treatment, Provides Hope for Patients with Unmet Medical Needsnnn

Published Mon, Mar 18 2024 12:01 PM UTC

Aligos Therapeutics, a prominent clinical stage biopharmaceutical company, has recently announced the initiation of the Phase 2a HERALD study of ALG-055009 in subjects with metabolic dysfunction-associated steatohepatitis (MASH). The study aims to address the unmet medical needs in liver and viral diseases and is a significant step for Aligos in developing novel therapeutics...

Aligos Therapeutics Inc

Revised headline: Aligos Therapeutics Inc Shows Strong Progress in Q3 2023 Despite Revenue Decline

Aligos Therapeutics Inc, a biopharmaceutical company specializing in the development of innovative therapies for liver diseases, recently released its financial results for the fiscal third quarter of 2023. Despite facing some challenges, the company demonstrated significant improvements in various aspects of its performance.
In terms of the company's financials, Aligos Therapeutics Inc managed to decrease its loss per share to $-0.41, showing improvement from the previous year's $-0.44 per share loss. Additionally, the company's earnings per share (EPS) improved from $-0.43 in the previous reporting period. These promising figures indicate Aligos Therapeutics Inc's progress in managing its losses and moving towards profitability.

Product Service News

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

Published Fri, Nov 3 2023 8:30 PM UTC


Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data on Emerging HBV Therapies
November 16 Event to feature KOL perspective on Emerging HBV Therapies
In the ever-evolving landscape of hepatitis B virus (HBV) therapies, Aligos Therapeutics has once again taken the lead by organizing a Knowledge-Opinion-Leader (KOL) event. T...






 

Aligos Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com